International pharmaceutical outsourcing provider, PCI Pharma Services, has completed installation and validation of a new serialisation suite at its newly acquired site in Ireland.
Ireland flag
This latest instalment expands the company’s serialisation capabilities to support customers prior to the implementation of the European Falsified Medicines Directive (EU FMD). The technology installed includes machine and human-readable coding, tamper evident solutions and Bollini labelling — which in turn is linked to a case loading and aggregation station, with a final aggregation station connecting cases to pallet.
“This is an important addition to the site’s capabilities and PCI as a whole. Ensuring supply chain integrity and patient safety is of critical importance. We pride ourselves on real-life experience and expertise in this area and our commitment through such significant strategic investment continues to demonstrate and deliver a truly industry-leading solution for our customers,” explained Ian Parsonage, PCI’s senior director of Global Serialization. “Being able to offer this fully flexible service and work in partnership with our customers from our site in the EU is essential ahead of the timelines for compliance with the EU FMD. Our customers also enjoy the benefits of a single B2B data exchange providing access to each site within our integrated global supply network. Having Dublin now commercial ready is one more seamless access point for supporting their global supply needs.”
This investment in the Dublin facility is part of a significant global initiative from PCI to develop its serialisation services across its global network, plans that will triple its overall serialisation capacity.